Anti-ATP6V1B2 antibody produced in rabbit
SIGMA/HPA008147 - Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Synonym: Anti-Endomembrane proton pump 58 kDa subunit; Anti-HO57; Anti-V-ATPase subunit B 2; Anti-V-type proton ATPase subunit B, brain isoform; Anti-Vacuolar proton pump subunit B 2
Product Type: Chemical
Enhanced Validation-Orthogonal RNAseq Confirmation Immunohistochemistry analysis in human cerebral cortex and skeletal muscle tissues using Anti-ATP6V1B2 antibody. Corresponding ATP6V1B2 RNA-seq data are presented for the same tissues.
Enhanced Validation-Orthogonal RNAseq Confirmation Western blot analysis in human cell lines SK-MEL-30 and MCF-7 using Anti-ATP6V1B2 antibody. Corresponding ATP6V1B2 RNA-seq data are presented for the same cell lines. Loading control: Anti-PFN1.
Immunohistochemistry Immunohistochemical staining of human cerebral cortex shows high expression.
Immunohistochemistry Immunohistochemical staining of human skeletal muscle shows low expression as expected.
Immunofluorescence Immunofluorescent staining of human cell line U-2 OS shows localization to vesicles.
Western Blotting Lane 1: Marker [kDa] 230, 130, 95, 72, 56, 36, 28, 17, 11 Lane 2: Human cell line RT-4 Lane 3: Human cell line U-251MG sp Lane 4: Human plasma (IgG/HSA depleted) Lane 5: Human liver tissue Lane 6: Human tonsil tissue
Western Blotting Western blot analysis in mouse cell line NIH-3T3 and rat cell line NBT-II.
Prestige Antibodies® Highly characterized and Enhanced Validated antibodies
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| conjugate | unconjugated |
| enhanced validation | orthogonal RNAseq Learn more about Antibody Enhanced Validation  |
| form | buffered aqueous glycerol solution |
| immunogen sequence | MALRAMRGIVNGAAPELPVPTGGPA |
| product line | Prestige Antibodies® Powered by Atlas Antibodies |
| Quality Level | 100 |
| shipped in | wet ice |
| species reactivity | rat, human, mouse |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunoblotting: 0.04-0.4 μg/mL |
| immunofluorescence: 0.25-2 μg/mL | |
| immunohistochemistry: 1:500-1:1000 | |
| UniProt accession no. | P21281  |
| Application: | All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information. |
| Biochem/physiol Actions: | ATP6V1B2 (ATPase, H+ transporting, V1 subunit B2) gene encodes a component of the vacuolar ATPase (V-ATPase), a multisubunit enzyme that is involved in the acidification of eukaryotic intracellular organelles. This acidification of organelles is important in processes such as protein sorting, zymogen activation, receptor-mediated endocytosis, and synaptic vesicle proton gradient generation. V-ATPase contains a cytosolic V1 domain that has ATPase activity and a transmembrane V0 domain involved in protein translocation. ATP6V1B2 encodes one of the two V1 domain B subunit isoforms. It is also called as lysosomal V1 subunit B2 or a brain isoform as it is abundantly expressed in the cerebrum and the organelle of lysosome. Mutations in this gene have been associated with DDOD (dominant deafness-onychodystrophy) syndrome. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| Features and Benefits: | Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section. Every Prestige Antibody is tested in the following ways: • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues. • Protein array of 364 human recombinant protein fragments. |
| Immunogen: | V-type proton ATPase subunit B, brain isoform recombinant protein epitope signature tag (PrEST) |
| Legal Information: | Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Other Notes: | Corresponding Antigen APREST71584 |
| Physical form: | Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |